NCT04188847 is a Phase 2 clinical trial of Chemotherapy plus apatinib in Recurrent Cervical Carcinoma, sponsored by Lei Li.

Who is sponsoring NCT04188847?

NCT04188847 is sponsored by Lei Li.

What drugs are being tested in NCT04188847?

Interventions in NCT04188847: Chemotherapy plus apatinib.

What condition does NCT04188847 study?

NCT04188847 studies Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Vascular Endothelial Growth Factor 2 Inhibitor, Apatinib, Targeted Therapy.

Is NCT04188847 still recruiting?

NCT04188847 is currently completed. Last updated 15 March 2022.

Last reviewed 2022-03-15 · How we verify

NCT04188847

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-line Chemotherapy for Recurrent Cervical Cancer

Completed Phase 2 Last updated 15 March 2022

What this trial tests

Phase 2 trial testing Chemotherapy plus apatinib in Recurrent Cervical Carcinoma in 37 participants. Completed in 13 March 2022.

Timeline

6 December 2019

Primary endpoint
6 February 2022

13 March 2022

Quick facts

Lead sponsor	Lei Li
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	6 December 2019
Primary completion	6 February 2022
Estimated completion	13 March 2022
Sites	1 location across China

Drugs / interventions tested

Chemotherapy plus apatinib — full drug profile →

Conditions studied

Recurrent Cervical Carcinoma — all drugs for Recurrent Cervical Carcinoma →
Persistent Advanced Cervical Carcinoma — all drugs for Persistent Advanced Cervical Carcinoma →
Chemotherapy — all drugs for Chemotherapy →
Vascular Endothelial Growth Factor 2 Inhibitor — all drugs for Vascular Endothelial Growth Factor 2 Inhibitor →

Sponsor

Lei Li — full company profile →

Who can join

Adults 18 to 75, female only, with Recurrent Cervical Carcinoma or Persistent Advanced Cervical Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients. A combination of cisplatin, paclitaxel and apatinib would be given for first 23 patients. If at least 13 patients achieved complete or partial remission, the same regimen would be given for rest patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms.
Yang S, Fei W, Zhao Y, Wang F, et al · · 2023 · cited 11× · PMID 37312935 · DOI 10.2147/ijn.s411761

Verify or expand the search:

Other recruiting trials for Recurrent Cervical Carcinoma

Currently open trials in the same condition.

NCT06157151 — PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cance · Phase 2 · recruiting
NCT06238635 — Dostarlimab and Cobolimab in Advanced Cervical Cancer · Phase 2 · active not recruiting
NCT04574635 — Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer · active not recruiting
NCT03968406 — Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers · Phase 1 · recruiting
NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M · Phase 2 · active not recruiting

Other Lei Li trials

Trials by the same sponsor.

NCT06558019 — Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence · not yet recruiting
NCT06557954 — Cervical Cytology DNA Methylation for Cervical Cancer Screening · not yet recruiting
NCT05801263 — ctDNA Methylation for Epithelial Ovarian Cancer · unknown
NCT05801276 — ctDNA Methylation for Detecting Ovarian Cancer · unknown
NCT06490380 — HRD Status Reference Standard Based on WGS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04188847 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lei Li
Last refreshed: 15 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04188847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing